Condition
High-risk Patients
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 3 (1)
P 4 (2)
Trial Status
Completed3
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05198960Phase 3Recruiting
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
NCT03933306Phase 4Completed
Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes
NCT04861337Phase 4Completed
Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients
NCT05410171Not ApplicableUnknownPrimary
Machine Learning-based Early Clinical Warning of High-risk Patients
NCT01539746Not ApplicableCompleted
Transcatheter Aortic Valve Implantation Without Predilation
Showing all 5 trials